Brief: Axovant Gene Therapies Signed A Strategic Partnership With Viralgen
Sept 15 (Reuters) - Axovant Gene Therapies Ltd AXGT.O :
* AXOVANT GENE THERAPIES LTD - SIGNED A STRATEGIC
PARTNERSHIP WITH
VIRALGEN
* AXOVANT GENE THERAPIES LTD - DATA FROM PHASE 1/2 CLINICAL
STUDY
OF AXO-AAV-GM1 IS EXPECTED IN Q4
* AXOVANT GENE THERAPIES LTD - ANTICIPATE IND CLEARANCE OF
AXO-AAV-GM2 IND APPLICATION BEFORE YEAR END
Source text for Eikon: ID:nGNX2FF1L7
Further company coverage: AXGT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sio Gene Therapies
See all newsBrief: Sio Gene Therapies Inc - On March 14, Got Notice That Nasdaq Has Determined That Company's Common Stock Will Be Delisted From Nasdaq Capital Market
Brief: Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
Brief: Sio Gene Therapies Inc. Announces Board Approval Of Plan Of Complete Liquidation, Dissolution
Brief: Sio Gene Therapies Announces Second Quarter Financial Results
Brief: Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results